| The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies. | |
| | |
MedLine Citation:
|
PMID: 20951732 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Imbalances in cancer cell redox homeostasis provide a platform for new opportunities in the development of anticancer drugs. The control of severe dose-limiting toxicities associated with redox regulation, including myelosuppression and immunosuppression, remains a challenge. Recent evidence implicates a critical role for redox regulation and thiol balance in pathways that control myeloproliferation, hematopoietic progenitor cell mobilization, and immune response. Hematopoietic stem cell (HSC) self-renewal and differentiation are dependent upon levels of intracellular reactive oxygen species (ROS) and niche microenvironments. Redox status and the equilibrium of free thiol:disulfide couples are important in modulating immune response and lymphocyte activation, proliferation and differentiation. This subject matter is the focus of the present review. The potential of redox modulating chemotherapeutics as myeloproliferative and immunomodulatory agents is also covered. |
| | |
Authors:
|
Christina L Grek; Danyelle M Townsend; Kenneth D Tew |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-10-15 |
Journal Detail:
|
Title: Pharmacology & therapeutics Volume: 129 ISSN: 1879-016X ISO Abbreviation: Pharmacol. Ther. Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-24 Completed Date: 2011-05-24 Revised Date: 2012-02-02 |
Medline Journal Info:
|
Nlm Unique ID: 7905840 Medline TA: Pharmacol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 172-84 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents / therapeutic use* Bone Marrow / drug effects*, immunology, metabolism*, physiology Cell Proliferation / drug effects Cytokines / metabolism Glutathione / metabolism Hematopoiesis Hematopoietic Stem Cells / cytology, drug effects, immunology, physiology Humans Immune System / drug effects*, metabolism Neoplasms / drug therapy*, immunology, metabolism Oxidation-Reduction / drug effects Protective Agents / therapeutic use* Reactive Oxygen Species / metabolism Sulfhydryl Compounds / metabolism* |
| Grant Support | |
ID/Acronym/Agency:
|
R01 CA085660-13/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Cytokines; 0/Protective Agents; 0/Reactive Oxygen Species; 0/Sulfhydryl Compounds; 70-18-8/Glutathione |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Regulation of monoamine transporters: Role of transporter phosphorylation.
Next Document: F?-isoprostane formation, measurement and interpretation: the role of exercise.